Relationship between viral clearance and prevention of carcinogenesis in patients with chronic hepatitis genotype2 treated with sofosuvubir plus ribavirin combination therapy
Not Applicable
- Conditions
- Chronic hepatitis C
- Registration Number
- JPRN-UMIN000018453
- Lead Sponsor
- ippon Medical School Chiba Hokusoh Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Not provided
Exclusion Criteria
1. History of allergy to sofosubuvir, Ribavirin, and other nucleotide analog. 2. severe renal disorder or chronic renal failure on hemodialysis 3. medication with carbamazepine, phenytoin, rifampicin, St. John's wort 4. pregnant woman or lactating mother 5. poorly controlled heart disease 6. hemoglobinopathy 7. severe depression 8. autoimmune hepatitis 9. Hepatocellular carcinoma, or other malignant tumor 10. severe liver disorder (T-Bil>3.0mg/dL, and/or PT%<70%, and/or Alb<3.4g/dL) 11. Judged by investigator not to be appropriate for inclusion in this study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method